Erkang Pharmaceutical announced that Mr. Shuai Fangwen, the controlling shareholder of the company, originally planned to reduce his holdings by no more than 42 million shares from April 23 to July 22, 2026, or 2.04% of the total share capital. As of the date of disclosure of the announcement, the period of the holdings reduction plan had expired. Shuai Fangwen reduced his holdings by 10.776 million shares through centralized bidding, accounting for 0.52% of the total share capital, and reduced his holdings at an average price of 4.38 yuan/share. After the holdings were reduced, Shuai Fangwen's shareholding fell to 843 million shares, accounting for 40.86% of the total share capital. This reduction in holdings will not lead to a change in the company's control, nor will it affect the company's governance structure and continued operation.

Erkang Pharmaceutical announced that Mr. Shuai Fangwen, the controlling shareholder of the company, originally planned to reduce his holdings by no more than 42 million shares from April 23 to July 22, 2026, or 2.04% of the total share capital. As of the date of disclosure of the announcement, the period of the holdings reduction plan had expired. Shuai Fangwen reduced his holdings by 10.776 million shares through centralized bidding, accounting for 0.52% of the total share capital, and reduced his holdings at an average price of 4.38 yuan/share. After the holdings were reduced, Shuai Fangwen's shareholding fell to 843 million shares, accounting for 40.86% of the total share capital. This reduction in holdings will not lead to a change in the company's control, nor will it affect the company's governance structure and continued operation.